reports
Heineken N.V. reports the progress of transactions under its current s...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 12 January 2026 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 5 January 2026 up to and including 9 January 2026 a total of 182,115 shares were repurchased on exchange at an average price of € 68.52. During the same period, 219,305 sh...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- ING Helpdesk
Benelux Morning Notes
BE Semiconductor Industries: Exceptional order intake supports strong FY26. Heineken: Back from the Brink. Wolters Kluwer: An acquisition and a new CP & ESG CEO. Staffing sector: US temp volume touch weaker vs November; downward revisions to Oct/Nov; NFP jobs miss expectations. Coverage change
CEO of Heineken N.V. to step down on 31 May 2026
CEO of Heineken N.V. to step down on 31 May 2026 CEO of Heineken N.V. to step down on 31 May 2026 Amsterdam, 12 January 2026 – Heineken N.V. today announced that CEO and Chairman of the Executive Board Dolf van den Brink has informed the Supervisory Board of his decision to step down from his position on 31 May 2026. After almost six years at the helm of HEINEKEN during which he has guided the Company through turbulent economic and political times, and with the EverGreen Strategy 2030 in place, Dolf has concluded, in consultation with the Supervisory Board, that this is the right time to h...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...
Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomput...
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...
Jensen Group NV: 1 director
A director at Jensen Group NV bought 5,000 shares at 57.660EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Zealand Pharma to present at the J.P. Morgan Healthcare Conference
Zealand Pharma to present at the J.P. Morgan Healthcare Conference Press release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, will take part in a presenta...
Heineken N.V. reports the progress of transactions under its current s...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 5 January 2026 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 29 December 2025 up to and including 2 January 2026 a total of 36,210 shares were repurchased on exchange at an average price of € 69.02. During the same period, 5,641 shar...
Total number of shares and voting rights in Zealand Pharma as of Decem...
Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which change...
Heineken N.V. reports the progress of transactions under its current ...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 29 December 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 22 December 2025 up to and including 26 December 2025 a total of 109,494 shares were repurchased on exchange at an average price of € 68.48. During the same period, 10...
Heineken N.V. reports the progress of transactions under its current ...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 22 December 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 15 December 2025 up to and including 19 December 2025 a total of 179,032 shares were repurchased on exchange at an average price of € 69.80. During the same period, 179,...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Phar...
- ING Helpdesk
Heineken N.V.: 1 director
A director at Heineken N.V. sold 7,000 shares at 68.000EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Heineken N.V. reports the progress of transactions under its current s...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 15 December 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 8 December 2025 up to and including 12 December 2025 a total of 182,810 shares were repurchased on exchange at an average price of € 68.36. During the same period, 182,76...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Thomas Couvreur
ABN Amro NIBC, Wealth & Staff reductions drive value; target price inc...
We have reviewed our model on ABN Amro, incorporating the NIBC acquisition, the ambitious growth targets in Wealth Management and the aggressive cost savings targets, mainly driven by FTE reductions. By FY28 we see our income estimates increase by 4.3% and cost estimates decrease by 3.1%. Our new SoTP valuation points to a target price of €29 (vs €25.5), reiterating our Hold recommendation given limited upside.
- Jacob Mekhael
Zealand Pharma CMD key takeaways
Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.